Daly Alex, Newman Lydia, Thomas Alexandra, Munro Alicia, Spence Cameron, Long Joe, Arnott Jonathan, Durkin Kesta, Layfield David, Heetun Adam, Wootton Stephen, Copson Ellen R, Cutress Ramsey I
Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Front Nutr. 2024 Apr 23;11:1366768. doi: 10.3389/fnut.2024.1366768. eCollection 2024.
Specific body composition markers derived from L3 axial computed tomography (CT) images predict clinical cancer outcomes, including chemotherapy toxicity and survival. However, this method is only applicable to those undergoing lumbar (L3) CT scanning, which is not universally conducted in early breast cancer cases. This study aimed to evaluate CT analysis at T4 as a feasible alternative marker of body composition in breast cancer.
All patients participated in the Investigating Outcomes from Breast Cancer: Correlating Genetic, Immunological, and Nutritional (BeGIN) Predictors observational cohort study (REC reference number: 14/EE/1297). Staging chest-abdomen-pelvic CT scan images from 24 women diagnosed with early breast cancer at University Hospital Southampton were analysed. Adipose tissue, skeletal muscle, and muscle attenuation were measured from the transverse CT slices' cross-sectional area (CSA) at T4 and L3. Adipose tissue and skeletal muscle area measurements were adjusted for height. Spearman's rank correlation coefficient analysis was used to determine concordance between body composition measurements using CT analysis at L3 and T4 regions.
Derived estimates for total adipose tissue, subcutaneous adipose tissue, and intramuscular adipose tissue mass following adjustment for height were highly concordant when determined from CSAs of CT slices at T4 and L3 (R = 0.821, < 0.001; R = 0.816, < 0.001; and R = 0.830, < 0.001). In this cohort, visceral adipose tissue (VAT) and skeletal muscle estimates following height adjustment were less concordant when measured by CT at T4 and L3 (R = 0.477, = 0.039 and R = 0.578, = 0.003). The assessment of muscle attenuation was also highly concordant when measured by CT at T4 and L3 (R = 0.840, < 0.001).
These results suggest that the CT analysis at T4 and L3 provides highly concordant markers for total adipose, subcutaneous adipose, and intramuscular adipose estimation, but not VAT, in this breast cancer population. High concordance between T4 and L3 was also found when assessing skeletal muscle attenuation. Lower concordance was observed for the estimates of skeletal muscle area, potentially explained by differences in the quantity and proportions of axial and appendicular muscle between the thorax and abdomen. Future studies will determine the value of T4 metrics as predictive tools for clinical outcomes in breast cancer.
源自L3轴位计算机断层扫描(CT)图像的特定身体成分标志物可预测临床癌症结局,包括化疗毒性和生存率。然而,该方法仅适用于接受腰椎(L3)CT扫描的患者,而早期乳腺癌病例并非普遍进行此项扫描。本研究旨在评估T4水平的CT分析作为乳腺癌身体成分的可行替代标志物。
所有患者均参与了乳腺癌研究:关联基因、免疫和营养(BeGIN)预测因子观察性队列研究(REC参考编号:14/EE/1297)。对南安普顿大学医院24例诊断为早期乳腺癌的女性患者的胸部-腹部-盆腔分期CT扫描图像进行分析。从T4和L3水平的CT横断面上测量脂肪组织、骨骼肌和肌肉衰减,并根据身高对脂肪组织和骨骼肌面积测量值进行校正。采用Spearman等级相关系数分析来确定L3和T4区域CT分析测量的身体成分之间的一致性。
校正身高后,根据T4和L3水平CT切片的横截面积(CSA)确定的总脂肪组织、皮下脂肪组织和肌内脂肪组织质量的估算值高度一致(R = 0.821,P < 0.001;R = 0.816,P < 0.001;R = 0.830,P < 0.001)。在该队列中,校正身高后,通过T4和L3水平CT测量的内脏脂肪组织(VAT)和骨骼肌估算值的一致性较低(R = 0.477,P = 0.039;R = 0.578,P = 0.003)。T4和L3水平CT测量的肌肉衰减评估也高度一致(R = 0.840,P < 0.001)。
这些结果表明,在该乳腺癌人群中,T4和L3水平的CT分析为总脂肪、皮下脂肪和肌内脂肪的估算提供了高度一致的标志物,但不适用于VAT。评估骨骼肌衰减时,T4和L3之间也具有高度一致性。骨骼肌面积估算值的一致性较低,这可能是由于胸部和腹部轴向和附属肌肉的数量及比例存在差异所致。未来研究将确定T4指标作为乳腺癌临床结局预测工具的价值。